Doshi Medicare Private Limited

Doshi Medicare Private Limited, established on February 24, 2006, is a private unlisted company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U51397MH2006PTC160027. Its authorized capital stands at ₹8.00 million, with a paid-up capital of ₹7.55 million. The registered office is located at Ground Floor, Manchram Building, Mayat Manzil, No. 344, S.V.P. Road, Girgaon, Mumbai, Maharashtra, 400044, India.

The company operates in the wholesale trade and commission trade sector, excluding motor vehicles and motorcycles, focusing on the distribution of pharmaceutical finished formulations. Doshi Medicare is part of the Doshi Group of Companies, a prominent entity in the pharmaceutical distribution industry in India. The group has been active since 1944, with Doshi Medicare serving as one of its flagship companies.

Doshi Medicare Private Limited specializes in the distribution of pharmaceutical finished formulations, including tablets, capsules, syrups, and injections. The company does not operate its own manufacturing facilities; instead, it sources products from various manufacturers to meet the diverse needs of its clientele. This approach allows Doshi Medicare to offer a wide range of pharmaceutical products without the complexities associated with manufacturing operations. The company's distribution network is designed to efficiently deliver these products to healthcare providers, including hospitals, nursing homes, and government and private institutions.

The leadership team at Doshi Medicare Private Limited comprises several key individuals:

• Mukesh Mahendrakumar Doshi: Director
• Maitri Yogesh Doshi: Director
• Hitesh Doshi Mukeshkumar: Managing Director
• Yogesh Mukeshkumar Doshi: Managing Director
• Surekha Mukeshkumar Doshi: Director
• Hetal Hitesh Doshi: Director

These individuals play pivotal roles in steering the company's strategic direction and operations. Their collective experience and leadership contribute to Doshi Medicare's standing in the pharmaceutical distribution sector.

Doshi Medicare Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in 81 shipments totaling $227,000 USD across eight products in four therapeutic categories. The top five exported products are:

• Daratumumab: $99,000 USD, Rank #4, 7.4% market share
• Rituximab: $56,000 USD, Rank #14, 0.3% market share
• Gatifloxacin: $27,000 USD, Rank #3, 3.4% market share
• Thalidomide: $15,000 USD, Rank #12, 0.8% market share
• Nilotinib: $14,000 USD, Rank #4, 1.1% market share

The primary therapeutic categories for these exports are Advanced Oncology (84.5%), Advanced Antibiotics (11.9%), and Brand Names & OTC Products (3.0%). Notably, the company's portfolio concentration is high, with the top five products accounting for 92.6% of the total export value. This indicates a strategic focus on specific high-value products within the oncology and antibiotic segments.

Doshi Medicare Private Limited has made strategic inroads into emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's focus on finished pharmaceutical formulations aligns with the growing healthcare needs in these regions. By leveraging the World Health Organization's (WHO) prequalification program, Doshi Medicare has enhanced its credibility and facilitated smoother market access. This prequalification ensures that the company's products meet international quality standards, which is crucial for gaining trust and regulatory approvals in these emerging markets.

Doshi Medicare's geographic strategy demonstrates a targeted approach to market expansion. The company's significant export activities in Advanced Oncology and Advanced Antibiotics suggest a strategic focus on high-demand therapeutic areas. However, the high concentration of export value in the top five products indicates a potential risk associated with over-reliance on a limited product range. Diversifying the product portfolio and exploring additional therapeutic categories could mitigate this risk and enhance the company's resilience in the global market.

As of the latest available data, Doshi Medicare Private Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. This suggests that the company may not currently have direct market access to the United States. The absence of FDA approvals could be due to various factors, including the company's strategic focus on other markets or the complexity of obtaining FDA approvals for pharmaceutical products. Further engagement with the FDA and compliance with regulatory requirements would be necessary for market entry into the U.S.

Doshi Medicare Private Limited's products are likely manufactured by third-party facilities that hold World Health Organization (WHO) Good Manufacturing Practice (GMP) certifications and European Union (EU) GMP certificates. While specific certifications for Doshi Medicare's products are not detailed, the company's focus on high-quality pharmaceutical formulations suggests adherence to international manufacturing standards. Ensuring that manufacturing partners maintain WHO and EU GMP certifications is essential for maintaining product quality and meeting regulatory requirements in various markets.

In India, Doshi Medicare Private Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company holds the necessary manufacturing licenses and approvals from state drug controllers to distribute pharmaceutical products. Additionally, Doshi Medicare has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. Compliance with these regulatory bodies ensures that the company's products meet national standards and are authorized for distribution both domestically and internationally.

As of the latest available information, there have been no reported Form 483 observations, warning letters, or import alerts issued to Doshi Medicare Private Limited. This indicates a clean regulatory record, suggesting that the company maintains compliance with applicable regulations and standards. Continuous adherence to regulatory requirements is crucial for sustaining the company's reputation and operational integrity in the pharmaceutical distribution sector.

Doshi Medicare Private Limited operates in a competitive pharmaceutical distribution market, facing competition from both domestic and international players. Key competitors include AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. These companies offer similar product portfolios and distribution services, intensifying the competitive dynamics. Doshi Medicare's focus on high-demand therapeutic areas, such as oncology and antibiotics, positions it strategically within the market. However, the company's high portfolio concentration in a few products may limit its ability to compete across a broader range of therapeutic categories.

Doshi Medicare Private Limited's key differentiators include its longstanding presence in the pharmaceutical distribution industry, being part of the Doshi Group established in 1944. The company's specialization in distributing finished pharmaceutical formulations, including oncology and antibiotic products, caters to specific market needs. Additionally, Doshi Medicare's focus on high-quality products and adherence to international manufacturing standards enhance its credibility and appeal to healthcare providers. However, the company's high portfolio concentration in a few products may limit its ability to offer a diversified range of therapeutic options.

Doshi Medicare Private Limited's current strategic direction centers on distributing high-demand pharmaceutical formulations, particularly in the oncology and antibiotic segments. The company's focus on finished products aligns with market needs and regulatory requirements. Looking ahead, expanding the product portfolio to include a broader range of therapeutic categories could enhance the company's market position and resilience. Additionally, exploring new geographic markets and strengthening regulatory compliance will be essential for sustaining growth and competitiveness in the evolving pharmaceutical distribution landscape.

Doshi Medicare Private Limited's track record in pharmaceutical distribution is characterized by a focus on high-quality finished formulations. The company's export volume and consistency indicate a reliable supply chain and operational efficiency. However, the high concentration of export value in a few products suggests a need for diversification to mitigate potential risks associated with over-reliance